Xenon Pharmaceuticals Inc. (XENE)
Fuera de horario:
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Suite 200
Burnaby, BC V5G 4W8
Canada
604 484 3300
https://www.xenon-pharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 251
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Ian C. Mortimer C.M.A., C.P.A., M.B.A. | President, CEO & Director | 1.07M | 2.37M | 1976 |
| Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer | 621.12k | N/D | 1979 |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer | 719.82k | N/D | 1971 |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery | 323.43k | N/D | 1961 |
| Ms. Sheila M. Grant M.B.A., M.Sc., MBA | Executive Vice President of R&D Operations | N/D | N/D | N/D |
Descripción
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Xenon Pharmaceuticals Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
